Loading...
Thumbnail Image
Item

Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression : a placebo-controlled, double-blind, randomised trial in the UK

Abstract
BackgroundAbout 30% of patients with depression treated with antidepressant medication do not respond sufficiently to the first agents used. Pramipexole might usefully augment antidepressant medication in such cases of treatment-resistant depression, but data on its effects and tolerability are scarce. We aimed to assess the efficacy and tolerability of pramipexole augmentation of ongoing antidepressant treatment, over 48 weeks, in patients with treatment-resistant depression.
Citation
Browning, M., Cowen, P. J., Galal, U., Baldwin, A., Cleare, A. J., Evans, J., Huys, Q. J. M., Kessler, D., Kurkar, M., Nixon, N., et al. (2025). Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression : a placebo-controlled, double-blind, randomised trial in the UK. The Lancet Psychiatry, 12 (8), pp.579-589.
Journal / Source Title
DOI
PMID
Publisher
Elsevier
Publisher’s URL
Publisher’s statement
2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Note / Copyright